STOCK TITAN

Absci Corporation - ABSI STOCK NEWS

Welcome to our dedicated page for Absci Corporation news (Ticker: ABSI), a resource for investors and traders seeking the latest updates and insights on Absci Corporation stock.

Absci Corporation (Nasdaq: ABSI) is a leading company that leverages the power of artificial intelligence to drive the next generation of drug discovery and development. Based in Vancouver, WA, Absci combines advanced AI technology with scalable wet lab processes, aiming to revolutionize the speed and efficacy of creating novel biologics.

Absci's core business revolves around its Integrated Drug Creation™ platform, which offers a unified approach to biologic drug discovery and cell line development. By optimizing multiple drug characteristics simultaneously, this platform accelerates the timeline from concept to clinic while increasing the probability of success in therapeutic development. The company is uniquely positioned to screen billions of cells per week, enabling rapid transformation from AI-designed antibodies to wet lab-validated candidates in as little as six weeks.

Recent achievements include the presentation of positive preclinical data for ABS-101, a potential best-in-class anti-TL1A antibody program. The company has initiated IND-enabling studies and plans to submit an Investigational New Drug application in the first quarter of 2025. Additionally, Absci has forged strategic partnerships, such as a high-profile collaboration with AstraZeneca aimed at advancing an AI-designed oncology candidate, potentially valued at up to $247 million.

Financially, Absci has strengthened its balance sheet through successful public offerings, raising approximately $86 million in gross proceeds. This financial boost ensures the company has the resources needed to advance its internal programs and continue investment in its groundbreaking platform.

Absci's innovative approach and commitment to leveraging AI for drug discovery have not only enhanced its internal pipeline but also attracted significant industry partnerships. The company’s vision of delivering breakthrough therapeutics at the click of a button continues to drive its mission forward, promising better and faster solutions for patients worldwide.

Rhea-AI Summary
Absci Corporation announces speaker lineup for R&D Day on October 4th, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.97%
Tags
none
-
News
Rhea-AI Summary
Absci Corporation announces its first R&D Day on October 4th, 2023 in New York City.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
conferences
-
Rhea-AI Summary
Absci Corporation (Nasdaq: ABSI) announces participation in upcoming investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.82%
Tags
conferences
Rhea-AI Summary
Absci Corporation has entered into a partnership with a Google Ventures-backed biotech company to discover new medicines and a collaboration with Caltech, supported by the Gates Foundation, to develop affordable HIV therapeutic vaccinations. The company reported a revenue of $3.4 million for Q2 2023, compared to $1.0 million in Q2 2022. Net loss for Q2 2023 was $41.7 million. Cash, cash equivalents, and short-term investments as of June 30, 2023, were $124.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
-
Rhea-AI Summary
Absci Corporation: Zach Jonasson, Ph.D., Appointed as CFO and CBO. Dr. Jonasson brings over 25 years of experience as an investor, entrepreneur, and operator, co-founding two venture capital firms and leading life science investment strategies. He will replace retiring CFO Greg Schiffman and join Absci's executive leadership team to lead the company into its next stage of growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.36%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.27%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
conferences AI
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
management

FAQ

What is the current stock price of Absci Corporation (ABSI)?

The current stock price of Absci Corporation (ABSI) is $4 as of November 4, 2024.

What is the market cap of Absci Corporation (ABSI)?

The market cap of Absci Corporation (ABSI) is approximately 449.7M.

What does Absci Corporation specialize in?

Absci specializes in using artificial intelligence and scalable wet lab technologies to accelerate the creation of novel biologics for therapeutic use.

What is Absci's Integrated Drug Creation™ platform?

The Integrated Drug Creation™ platform optimizes multiple drug characteristics simultaneously, speeding up the transition from concept to clinic and increasing the probability of success in development.

What are some of Absci's recent achievements?

Recent achievements include presenting positive preclinical data for ABS-101, initiating IND-enabling studies, and partnering with AstraZeneca for an AI-designed oncology candidate.

How has Absci strengthened its financial position?

Absci has strengthened its financial position through public offerings, raising approximately $86 million in gross proceeds to fund its internal programs and platform investments.

What is the significance of Absci's collaboration with AstraZeneca?

The collaboration with AstraZeneca combines Absci's AI drug creation platform with AstraZeneca's oncology expertise, aiming to advance a new AI-designed cancer treatment candidate valued at up to $247 million.

Where are Absci's main operational facilities located?

Absci's headquarters is in Vancouver, WA, with an AI Research Lab in New York City and an Innovation Center in Zug, Switzerland.

What is the timeline for ABS-101's clinical trials?

Absci expects to submit an IND for ABS-101 in the first quarter of 2025 and initiate Phase 1 clinical studies shortly thereafter.

How does Absci's AI technology contribute to drug discovery?

Absci's AI technology enables rapid screening and design of drug candidates, optimizing multiple characteristics important to both development and therapeutic benefit, thus accelerating the overall drug discovery process.

What are some of the internal programs Absci is focusing on?

Absci is focusing on several internal programs, including ABS-101 for anti-TL1A, ABS-201 for dermatology, and ABS-301 for immuno-oncology, alongside advancing additional internal asset programs.

How can interested parties stay updated on Absci's developments?

Interested parties can stay updated by visiting Absci's website and investor relations page, where they routinely post investor presentations, SEC filings, press releases, and webcasts.

Absci Corporation

Nasdaq:ABSI

ABSI Rankings

ABSI Stock Data

449.68M
113.56M
20.32%
61.12%
11.64%
Biotechnology
Services-commercial Physical & Biological Research
Link
United States of America
VANCOUVER